Archives of Clinical Infectious Diseases

Published by: Kowsar

Evaluation of Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Sepsis

Mitra Barati 1 , * , Mehdi Shekarabi 1 , Saeed Chobkar 2 , Mahshid Talebi-Taher 3 and Newsha Farhadi 4
Authors Information
1 Pediatric Infectious Diseases Research Centre, Iran University of Medical Sciences, Tehran, IR Iran
2 Department of Internal Medicine, Iran University of Medical Sciences,Tehran, IR Iran
3 Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, IR Iran
4 Medical Faculty, Shahed University, Tehran, Iran
Article information
  • Archives of Clinical Infectious Diseases: January 30, 2015, 10 (1); e26346
  • Published Online: January 25, 2015
  • Article Type: Research Article
  • Received: September 23, 2014
  • Accepted: September 25, 2014
  • DOI: 10.5812/archcid.26346

To Cite: Barati M, Shekarabi M, Chobkar S, Talebi-Taher M, Farhadi N. Evaluation of Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Sepsis, Arch Clin Infect Dis. 2015 ; 10(1):e26346. doi: 10.5812/archcid.26346.

Copyright © 2015, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Bochud PY, Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ. 2003; 326(7383): 262-6[PubMed]
  • 2. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003; 29(4): 530-8[DOI][PubMed]
  • 3. Spapen HD, Hachimi-Idrissi S, Corne L, Huyghens LP. Diagnostic markers of sepsis in the emergency department. Acta Clin Belg. 2006; 61(3): 138-42[DOI][PubMed]
  • 4. Dekkers PE, ten Hove T, te Velde AA, van Deventer SJ, van Der Poll T. Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia. Infect Immun. 2000; 68(4): 2156-60[PubMed]
  • 5. Slot O, Brunner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis. 1999; 58(8): 488-92[PubMed]
  • 6. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care. 2007; 11(2)[DOI][PubMed]
  • 7. Molkanen T, Ruotsalainen E, Thorball CW, Jarvinen A. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2011; 30(11): 1417-24[DOI][PubMed]
  • 8. Lawn SD, Myer L, Bangani N, Vogt M, Wood R. Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa. BMC Infect Dis. 2007; 7: 41[DOI][PubMed]
  • 9. Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd RF, 3rd.. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood. 1995; 86(1): 203-11[PubMed]
  • 10. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009; 27(3): 157-72[DOI][PubMed]
  • 11. Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med. 2012; 38(9): 1418-28[DOI][PubMed]
  • 12. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340(6): 448-54[DOI][PubMed]
  • 13. Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Melot C, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest. 2003; 123(6): 2043-9[PubMed]
  • 14. Sierra R, Rello J, Bailen MA, Benitez E, Gordillo A, Leon C, et al. C-reactive protein used as an early indicator of infection in patients with systemic inflammatory response syndrome. Intensive Care Med. 2004; 30(11): 2038-45[DOI][PubMed]
  • 15. Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care. 2004; 8(4)-42[DOI][PubMed]
  • 16. Boonstra MC, Verspaget HW, Ganesh S, Kubben FJ, Vahrmeijer AL, van de Velde CJ, et al. Clinical applications of the urokinase receptor (uPAR) for cancer patients. Curr Pharm Des. 2011; 17(19): 1890-910[PubMed]
  • 17. Jo M, Thomas KS, Wu L, Gonias SL. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J Biol Chem. 2003; 278(47): 46692-8[DOI][PubMed]
  • 18. Mizukami IF, Todd RF, 3rd.. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells. J Leukoc Biol. 1998; 64(2): 203-13[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments